Juergen Kurz – General Manager, HEUFT China
Juergen Kurz takes us through HEUFT’s unique technology that is revolutionizing the quality of packaging in the pharmaceutical industry in a country, China, where quality compliance is now an issue. …
Company info
HEUFT has its headquarters in Germany since 1979. They established an affiliate in China in 2003. They manufacture quality control machines for pharmaceuticals. They are also involved in the food and beverages industry.
“Quality, safety and efficiency: this is what matters when filling and packaging beverages, food and pharmaceuticals! The modular solutions from HEUFT SYSTEMTECHNIK GMBH put these key factors into practice simply and effectively. They ensure, during maximum productivity, that only perfect products reach the market.”
Address Plant 2, No.351, Chengjian Road, Minhang Shanghai 201108
Tel 0086 13801889286
Website https://heuft.com/en/
Email juergen.kurz@heuft.com
Juergen Kurz takes us through HEUFT’s unique technology that is revolutionizing the quality of packaging in the pharmaceutical industry in a country, China, where quality compliance is now an issue. …
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
Bridge Consulting’s Zoe Leung examines the journeys of Chinese-developed COVID-19 vaccines outside of China’s borders, drawing on a number of examples, from Sinopharm’s work on boosting vaccine supply in the…
Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a vaccine that uses mRNA technology, either…
The latest news from Chinese healthcare and pharma including Western pharmacos’ moves to license therapies from Chinese partners to sell globally, the seismic impact of new COVID lockdown restrictions in…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Jessie Zhu of Deltamed Co. Ltd./Pharmaron Clinical and Monica Juping Xu of Taimei Medical Technology outline the progress of…
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
A selection of recent top stories from the Chinese pharma industry, including China’s conditional approval of Pfizer’s COVID treatment pill Paxlovid; a new push to combat monopoly practices and unfair…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…
The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and…
The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention…
See our Cookie Privacy Policy Here
